Favorable News Coverage Somewhat Unlikely to Impact Prothena Corporation PLC (NASDAQ:PRTA) Share Price
News stories about Prothena Corporation PLC (NASDAQ:PRTA) have trended positive on Saturday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prothena Corporation PLC earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 48.429684645449 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : August 11, 2017 (finance.yahoo.com)
- Q3 2017 EPS Estimates for Prothena Corporation PLC Decreased by Analyst (NASDAQ:PRTA) (americanbankingnews.com)
- Q3 2017 EPS Estimates for Prothena Corporation PLC Lifted by Analyst (NASDAQ:PRTA) (americanbankingnews.com)
- Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment – Nasdaq (nasdaq.com)
- Alliancebernstein LP Increases Its Ownership in Prothena Corporation plc – Ordi (PRTA) – Modern Readers (modernreaders.com)
Several equities research analysts recently issued reports on the company. ValuEngine downgraded Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a report on Saturday, May 27th. Zacks Investment Research downgraded Prothena Corporation PLC from a “buy” rating to a “hold” rating in a report on Monday, May 15th. Oppenheimer Holdings, Inc. set a $70.00 price objective on Prothena Corporation PLC and gave the company a “buy” rating in a report on Thursday, May 11th. Jefferies Group LLC assumed coverage on Prothena Corporation PLC in a report on Monday, July 10th. They issued a “buy” rating and a $100.00 price objective on the stock. Finally, BTIG Research assumed coverage on Prothena Corporation PLC in a report on Friday, May 19th. They issued a “buy” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $77.09.
Prothena Corporation PLC (NASDAQ:PRTA) traded up 2.73% on Friday, reaching $57.16. The company had a trading volume of 267,063 shares. The stock’s market capitalization is $2.19 billion. Prothena Corporation PLC has a 12 month low of $40.58 and a 12 month high of $69.53. The firm has a 50-day moving average of $60.52 and a 200-day moving average of $54.91.
Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company had revenue of $26.81 million for the quarter, compared to analyst estimates of $16.08 million. During the same period last year, the company posted ($1.18) earnings per share. The firm’s revenue was up 7951.1% compared to the same quarter last year. On average, equities research analysts expect that Prothena Corporation PLC will post ($4.54) earnings per share for the current fiscal year.
In other Prothena Corporation PLC news, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $324,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $58.11, for a total value of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares in the company, valued at $368,707.95. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.